NCT02569320 is a Phase 1 clinical trial of Dexamethasone in Recurrent Plasma Cell Myeloma, sponsored by Ohio State University Comprehensive Cancer Center.

Who is sponsoring NCT02569320?

NCT02569320 is sponsored by Ohio State University Comprehensive Cancer Center.

What drugs are being tested in NCT02569320?

Interventions in NCT02569320: Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis, Pomalidomide.

What condition does NCT02569320 study?

NCT02569320 studies Recurrent Plasma Cell Myeloma.

Is NCT02569320 still recruiting?

NCT02569320 is currently completed. Last updated 15 June 2021.

Last reviewed 2021-06-15 · How we verify

NCT02569320

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Completed Phase 1 Last updated 15 June 2021

What this trial tests

Phase 1 trial testing Dexamethasone in Recurrent Plasma Cell Myeloma in 9 participants. Completed in 10 March 2021.

Timeline

20 May 2016

Primary endpoint
14 November 2020

10 March 2021

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	20 May 2016
Primary completion	14 November 2020
Estimated completion	10 March 2021
Sites	1 location across United States

Drugs / interventions tested

Dexamethasone (dexamethasone) — full drug profile →
HDAC Inhibitor AR-42 — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Pomalidomide — full drug profile →

Conditions studied

Recurrent Plasma Cell Myeloma — all drugs for Recurrent Plasma Cell Myeloma →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Recurrent Plasma Cell Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a drug used in chemotherapy that works to stop the growth of cancer cells by causing them to die. Giving HDAC inhibitor AR-42 together with pomalidomide may cause patients to respond better to treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
Zeng Z, Fu M, Hu Y, Wei Y, et al · · 2023 · cited 93× · PMID 37853437 · DOI 10.1186/s12943-023-01877-w
Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Hadden MJ, Advani A. · · 2018 · cited 61× · PMID 30189630 · DOI 10.3390/ijms19092630
The role of epigenomics in personalized medicine.
Kronfol MM, Dozmorov MG, Huang R, Slattum PW, et al · · 2017 · cited 43× · PMID 29276780 · DOI 10.1080/23808993.2017.1284557
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z
MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics.
Teodori L, Sestili P, Madiai V, Coppari S, et al · · 2020 · cited 37× · PMID 33363465 · DOI 10.3389/fphar.2020.582003
Epigenetics: A primer for clinicians.
Paluch BE, Naqash AR, Brumberger Z, Nemeth MJ, et al · · 2016 · cited 37× · PMID 26969414 · DOI 10.1016/j.blre.2016.02.002
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.
Pu J, Liu T, Wang X, Sharma A, et al · · 2024 · cited 36× · PMID 38654286 · DOI 10.1186/s40164-024-00507-5

Verify or expand the search:

Other trials of Dexamethasone

Trials testing the same drug.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Recurrent Plasma Cell Myeloma

Currently open trials in the same condition.

NCT04756401 — Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple M · Phase 2 · active not recruiting
NCT05363111 — Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT05391750 — Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma · Phase 1 · active not recruiting
NCT05514990 — Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AM · Phase 1, PHASE2 · active not recruiting
NCT05312255 — Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple · NA · recruiting

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02569320 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
Last refreshed: 15 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02569320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing